In the future, therapies which can restore sensitivity of lymphoma cells to TGF-β growth control by inducing Smad1/5 signalling can be helpful in treatment of B-cell lymphoma patients. Here, SMAD1 is linked to B-cell non-Hodgkin lymphoma.